Today's Rundown Featured Story | | | Thursday, June 28, 2018 Akebia Therapeutics is set to merge with Keryx Biopharmaceuticals. The combined company will own potentially complementary kidney disease drugs and a sales force to promote them, setting it up to fend off competition from rivals including FibroGen and GlaxoSmithKline. |
|
|
Top Stories Thursday, June 28, 2018 Novo Holdings has invested CHF 20 million ($20 million) in NBE Therapeutics, doubling the size of the startup’s series B round. NBE will use the money to start testing anti-ROR1 antibody-drug conjugate (ADC) NBE-002 in solid tumor patients. Thursday, June 28, 2018 Following the sudden resignation of Vipin Garg, its president and CEO, Neos Therapeutics has poached AgeneBio chief executive Jerry McLaughlin to fill the top spot, effective immediately. Monday, June 25, 2018 The increasing demand for innovation in research and the related pressures to deliver on the most promising findings from discovery are also driving the need for simultaneous innovation in the technologies that enable that innovation and, likewise, the reliance on data management solutions that respond to an increasingly complex scientific environment. Thursday, June 28, 2018 Appello Pharmaceuticals raised $10.5 million to fund development of a new treatment for Parkinson’s disease licensed from Vanderbilt University’s Center for Neuroscience Drug Discovery. Monday, June 25, 2018 Roche is integrating its mySugr diabetes management tool into Care Innovations’ telehealth service. The collaborators see the combination of their technologies facilitating remote care of people with diabetes and better management of the condition. Thursday, June 28, 2018 The team behind a much-hyped cancer-killing virus reports an "encouraging" 21% long-term survival rate in glioblastoma patients. But the number of patients who survived may be too small to know for sure if the treatment works. Enrollment Showcase | | | Sponsored by: Bioinformatics at UTHealth SBMI UTHealth SBMI now offers a M.S. track in clinical and translational bioinformatics. |
|
|
Resources Life Science Strategy Group Take this anonymous 10-minute survey to share your thoughts on leading eClinical technology solutions and earn up to $55 honoraria. Take the survey now! Sponsored by: Blue Latitude Health Blue Latitude Health explores the commercial barriers and new stakeholder connections for pharma companies developing precision medicines, and reveals how to grasp novel opportunities in the new era of healthcare. Presented By: Covance A solid RBM plan will not only help you comply with the ICH guidelines, but will help you mitigate risks which could ultimately delay your trials and increase costs. Download today! Presented by: Patheon, part of Thermo Fisher Scientific “Faster and better” has become the mantra for biopharmaceutical companies as they face intense pressure to get therapies to market faster. Quickly proving efficacy in first-in-human (FIH) trials is a make-or-break milestone for these cash-strapped companies whose hopes hinge upon one or two molecules. Read how CDMOs are responding to this pressure. Sponsored by: Seton Hall Law 4-day interactive educational program trusted by multi-national companies as part of their compliance training for employees. Explore legal, regulatory and ethical issues faced by pharmaceutical, biotech and medical device manufacturers operating globally. Visit event homepage for session topics. Sponsored by: Docusign Life science companies are experiencing a significant transformation in how they bring new products to market. | 
